Results 111 to 120 of about 42,502 (303)

Effect of Hewei Anshen Decoction on depressive insomnia and brain neurotransmitter levels

Sleep Research, EarlyView.
Abstract Objective To evaluate the therapeutic effect of Hewei Anshen Decoction (HAD) on both depressive symptoms and sleep quality in patients with depressive insomnia, and to investigate its impact on brain neurotransmitter levels. Methods Seventy‐two patients with depressive insomnia were randomly assigned to a treatment group and a control group ...
Feifei Lv, Xin Zhang, Liang Wang, Shaodan Li, Fagen Li   +4 more
wiley   +1 more source

A Case Series of Neuropsychological Outcome After Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Refractory Obsessive–Compulsive Disorder

, 2021
Neuromodulation: Technology at the Neural Interface, EarlyView.
Tim A. M. Bouwens van der Vlis, Annelien A. Duits   +1 more
wiley   +1 more source

Imipramine Increases Norepinephrine and Serotonin in the Salivary Glands of Rats

Biology
Xerostomia induced by antidepressants such as imipramine has long been thought to be due to their anticholinergic effects. However, even antidepressants with low anticholinergic effects may have a high incidence of xerostomia.
Kosuke Shirose, Masanobu Yoshikawa, Takugi Kan, Masaaki Miura, Mariko Watanabe, Mitsumasa Matsuda, Hiroyuki Kobayashi, Mitsuru Kawaguchi, Kenji Ito, Takeshi Suzuki   +9 more
doaj   +1 more source

Women's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue. Objectives To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them. Search Strategy Embase, MEDLINE,
Sarah Bunnewell, Sabrina Keating, Jo Parsons, Martha Hickey, Sarah Hillman   +4 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Brief report: Ketamine‐assisted “bridge therapy” for opioid tapering in complex cases

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25‐year‐old woman with OUD, chronic pain, and major depressive disorder underwent an 8‐week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Results Methadone
Mariana C. de Oliveira, Cláudia C. de Araujo Palmeira, André B. Negrão, Ziyad A. Hadi, Julia R. Arana, Rita de Cássia Ferreira Duarte, Joice L. P. da Silva, Gustavo K. Matsui, João F. D. Rapozero, Douglas H. Crispim, André Malbergier, João M. Castaldelli‐Maia   +11 more
wiley   +1 more source

The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning

, 2012
Holden D. Brown, Dionisio A. Amodeo, John A. Sweeney, Michael E. Ragozzino   +3 more
openalex   +2 more sources

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source